FLGT News and Press, Fulgent Genetics Inc. From 07/14/21

During the COVID-19 pandemic, Fulgent Genetics (NASDAQ: FLGT) was in the right place at the right time . Fulgent became a key provider of COVID-19 testing in 2020 and saw its revenue explode by almost 1,300% over the prior year. Few companies benefited more during the pandem...

Although the pandemic has mostly faded from the front pages, mutations of the SARS-CoV-2 virus are increasing the odds that COVID will make a resurgence this winter. Add in many Americans' hesitancy over vaccines, and it appears the companies providing testing, treatments, and vaccine boost...

During last year's market crash, many investors were shell-shocked by the rapid and sudden decline of the stock market. And with the markets now at all-time highs, there are concerns that another crash may not be too far away. At the very least, many stocks are vulnerable to corrections giv...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Thanumporn Thongkongkaew/iStock via Getty Images S3 Partners updates on the U.S. stocks with the highest percentage of short interest as the calendar turns to the second half of the year. While the average short interest as a percentage of total float for a U.S. stock is 5.39%, the list of na...

Fulgent Genetics (NASDAQ: FLGT) is arguably the cheapest coronavirus stock on the market -- if not the cheapest biotech of any type out here, with a price-to-earnings (P/E) valuation of just 6.6. What's more, the company has about $697.4 million in cash on its balance shee...

With U.S. cases of COVID-19 down more than 90% from their January peak, it might seem like an odd time to invest in a company that attributes more than 90% of last year's business to testing for the disease. Unfortunately, several new strains of the virus that cause COVID-19 have been sprea...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sometimes, a risky stock just isn’t worth the trouble. But for this article, when I say high-risk stocks, I’m implying that these are high- reward stocks as well. There’s no point adding to your risk p...

At the conclusion of the 2021 Russell indexes annual reconstitution, following notable healthcare stocks will join the Russell Microcap Index, effective June 28 after the U.S. market opens.Asensus Surgical (ASXC), Organovo Holdings (ONVO), Senseonics Holdings (SENS), Clovis Onc...

Fulgent is one of the emerging players in the highly fragmented genetic testing market. The company astutely strengthened its credibility and proved its capability by playing a key role in COVID-19 testing. The ability to scale rapidly to meet COVID-19 testing demands has given it...